Monday, 16 November 2026Follow on 𝕏

Deal tracker

Biopharma acquisitions, licensing deals and partnerships, updated automatically every day from company announcements and filings. Values are headline figures in US dollars, including milestone payments where disclosed.

Deals in 2026
12
Disclosed value
$45bn
Largest deal
$19bn
AnnouncedBuyer or partnerTarget or assetTypeValueStatusSource
16 Nov 2026 Novartis OBI PharmaNext-generation ADC platform Licensing $2bn$30mn upfront Announced Source β†—
11 Nov 2026 AstraZeneca OmnioseVaccine platform Acquisition Undisclosed Completed Source β†—
9 Nov 2026 Argenx Unnatural ProductsMacrocyclic peptide discovery Acquisition $1.1bn$550mn upfront Announced Source β†—
9 Nov 2026 CorMedix Heron TherapeuticsPost-operative pain and nausea medicines Asset purchase $200mn$145mn upfront Announced Source β†—
21 Oct 2026 Merck KGaA Silence TherapeuticsDivesiran Acquisition $1.1bn Announced Source β†—
8 Oct 2026 Viatris Pacira BioSciences Acquisition $1.6bn Announced Source β†—
31 Aug 2026 Eli Lilly Merida BiosciencesMER511 Acquisition $2.9bn Announced Source β†—
27 Jul 2026 Argenx Forte BiosciencesFB102 Acquisition $2.2bn Completed Source β†—
16 Jul 2026 Eli Lilly AtaiBeckleyPsychedelic medicines Acquisition $3.8bn Announced Source β†—
29 Jun 2026 Zymeworks Theravance Biopharma Acquisition $929mn Announced Source β†—
18 Jun 2026 AbbVie Apogee Therapeutics Acquisition $11bn Announced Source β†—
30 Jan 2026 AstraZeneca CSPC Pharmaceutical GroupEight weight-management programmes Licensing $19bn$1.2bn upfront Announced Source β†—